Chronic urticaria is defined as the presence of spontaneously occurring wheals with pruritus lasting at least 6 weeks, sometimes accompanied with angioedema. It may be idiopathic or autoimmune as defined by the presence of the IgG anti-IgE receptor, �...
Chronic urticaria is defined as the presence of spontaneously occurring wheals with pruritus lasting at least 6 weeks, sometimes accompanied with angioedema. It may be idiopathic or autoimmune as defined by the presence of the IgG anti-IgE receptor, α subunit antibodies, or IgG anti-IgE antibodies. Recent treatment guideline recommends the use of non-sedating antihistamines up to fourfold dosage as the first line of treatment, followed by leukotriene antagonist, and lastly systemic immunosuppressants or omalizumab. Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of IgE. A 14-year-old male presented with chronic urticaria. Along the guideline, he was treated by high-dose anti-histamines, corticosteroids and cyclosporine and no improvement was shown. So we decided to use omalizumab. The patient experienced a remarkable response to omalizumab. But during the observation period, the response disappeared and showed flare-ups. He had been injected omalizumab for 4 times. Along the injection schedule, the symptoms were repeated wax and wane. In conclusion, omalizumab is an excellent treatment choice for those who with severe, chronic refractory urticaria usually recommended treatments with prednisone. However, it does not seem to be a cure for the disease, but a symptomatic treatment. Herein, we report the case of the effects of omalizumab in the treatment of chronic urticaria.